🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Mantle Cell Lymphoma

CONFIRM: Magnetic Resonance Guided Radiation Therapy NCT04368702NA2 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: Viewray MRIdian® Linac BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma NCT06854003Phase 27 sites📍 Phoenix📍 Boston📍 Boston Christine Ryan · Tests: Bendamustine, Rituximab, Cytarabine, Zanubrutinib, Sonrotoclax A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07377578Phase 32 sites📍 Beijing📍 Nanning Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Rocbrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib, Orelabrutinib A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) NCT06742996Phase 3145 sites📍 Birmingham📍 Tucson📍 Fresno BeOne Medicines · Tests: Sonrotoclax, Zanubrutinib, Placebo Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT05910801Phase 22 sites📍 Rochester📍 Houston Academic and Community Cancer Research United · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354n/a1 site📍 Palo Alto Adaptive Biotechnologies · Tests: ClonoSEQ Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07460362Phase 21 site📍 Beijing Peking University Third Hospital · Tests: Glofitamab, Lenalidomide BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites📍 Duarte📍 Stanford📍 Kansas City PeproMene Bio, Inc. · Tests: BAFFR-CAR T cells Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients NCT06263491Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Rituximab, Pirtobrutinib A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma NCT06084936Phase 383 sites📍 Berkeley📍 Duarte📍 Los Angeles Hoffmann-La Roche · Tests: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax NCT05724121n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT06675123Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, BTK Inhibitor A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492 Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma NCT07673367Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL NCT06363994Phase 339 sites📍 Beijing📍 Beijing📍 Bengbu InnoCare Pharma Inc. · Tests: Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma NCT06839053Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma NCT04491370Phase 1, Phase 21 site📍 Valhalla New York Medical College · Tests: Polatuzumab vedotin A Study of ARC-02 in B-cell NHL NCT07691606Phase 129 sites📍 Los Angeles📍 Louisville📍 New York Taiho Oncology, Inc. · Tests: ARC-02, Rituximab Liquid Biopsy in Mature B-cell Tumors NCT03280394n/a1 site📍 Bellinzona Oncology Institute of Southern Switzerland · Tests: Liquid Biopsy Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment NCT06496308Phase 31 site📍 Shanghai Ruijin Hospital · Tests: Orelabrutinib, Bendamustine, Rituximab, Venetoclax Auto Stem Cell Transplant for Lymphoma Patients NCT03125642Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL NCT06553872Phase 23 sites📍 Stanford📍 Miami📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Pirtobrutinib, Brexucabtagene Autoleucel Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites📍 Heidelberg📍 Heidelberg University Hospital Heidelberg · Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma NCT03501576n/a2 sites📍 Atlanta📍 Atlanta Emory University · Tests: Inactivated Influenza Vaccine Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. ZR2 Sequential Immunochemotherapy for Newly Treated MCL NCT05992597Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: ZR2 RDHAP A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma NCT06136351Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Zanubrutinib, Rituximab, Bendamustin
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy